Verastem, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Verastem, Inc. (VSTM) reported Revenue from Contract with Customer, Excluding Assessed Tax of $10.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-03-20
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $0.00.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $10.00M.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $0.00.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $10.00M.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.60M, a 26.45% increase from fiscal 2021.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $2.05M, a 97.68% decline from fiscal 2020.
- Verastem, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $88.52M, a 407.08% increase from fiscal 2019.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $10.00M derived: sum of 3 quarters · filed 2025-03-20 | $10.00M 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $10.00M derived: sum of 2 quarters · filed 2024-11-06 | $10.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $10.00M 10-Q · filed 2024-08-08 | $10.00M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $2.60M 10-K · filed 2025-03-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $2.60M 10-Q · filed 2023-11-08 | $3.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.60M 10-Q · filed 2023-08-08 | $3.14M derived: sum of 3 quarters · filed 2023-08-08 | $3.14M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.60M 10-Q · filed 2023-05-09 | $3.14M derived: sum of 2 quarters · filed 2023-05-09 | $3.14M derived: sum of 3 quarters · filed 2023-05-09 | $3.64M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $545.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $547.00K derived: sum of 2 quarters · filed 2023-03-14 | $1.05M derived: sum of 3 quarters · filed 2023-03-14 | $2.05M 10-K · filed 2023-03-14 |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-03 | $502.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.51M 10-Q · filed 2022-11-03 | $2.01M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $500.00K 10-Q · filed 2022-08-08 | $1.51M 10-Q · filed 2022-08-08 | $2.01M derived: sum of 3 quarters · filed 2022-08-08 | $80.66M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-09 | $1.51M derived: sum of 2 quarters · filed 2022-05-09 | $80.16M derived: sum of 3 quarters · filed 2022-05-09 | $84.47M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $506.00K 10-K · filed 2021-03-18 | $79.15M derived: sum of 2 quarters · filed 2021-11-04 | $83.46M derived: sum of 3 quarters · filed 2021-11-04 | $88.52M 10-K · filed 2023-03-14 |
| 2020-09-30 | $78.65M 10-Q · filed 2021-11-04 | $82.95M derived: sum of 2 quarters · filed 2021-11-04 | $88.01M 10-Q · filed 2021-11-04 | $91.63M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $4.31M 10-Q · filed 2021-08-02 | $9.36M 10-Q · filed 2021-08-02 | $12.98M derived: sum of 3 quarters · filed 2021-08-02 | $22.01M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | $5.06M 10-Q · filed 2021-05-11 | $8.67M derived: sum of 2 quarters · filed 2021-05-11 | $17.70M derived: sum of 3 quarters · filed 2021-05-11 | $20.84M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $3.62M 10-K · filed 2021-03-18 | $12.65M derived: sum of 2 quarters · filed 2021-03-18 | $15.79M derived: sum of 3 quarters · filed 2021-03-18 | $17.46M 10-K · filed 2022-03-28 |
| 2019-09-30 | $9.03M 10-K · filed 2021-03-18 | $12.17M derived: sum of 2 quarters · filed 2021-03-18 | $13.84M 10-Q · filed 2020-11-09 | $15.05M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $3.14M 10-K · filed 2021-03-18 | $4.81M 10-Q · filed 2020-08-10 | $6.02M derived: sum of 3 quarters · filed 2021-03-18 | $21.52M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $1.67M 10-K · filed 2021-03-18 | $2.88M derived: sum of 2 quarters · filed 2021-03-18 | $18.39M derived: sum of 3 quarters · filed 2021-03-18 | $28.39M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $1.21M 10-K · filed 2020-03-11 | $16.72M derived: sum of 2 quarters · filed 2020-03-11 | $26.72M derived: sum of 3 quarters · filed 2020-03-11 | $26.72M 10-K · filed 2021-03-18 |
| 2018-09-30 | $15.51M 10-K · filed 2020-03-11 | $25.51M derived: sum of 2 quarters · filed 2020-03-11 | $25.51M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $10.00M 10-K · filed 2020-03-11 | $10.00M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |